Q2 2022 13F Holders as of 6/30/2022
-
Type / Class
-
Equity / COMMON STOCK
-
Shares outstanding
-
79.4M
-
Number of holders
-
102
-
Total 13F shares, excl. options
-
34.7M
-
Shares change
-
-348K
-
Total reported value, excl. options
-
$328M
-
Value change
-
-$12M
-
Put/Call ratio
-
0
-
Number of buys
-
56
-
Number of sells
-
-36
-
Price
-
$9.45
Significant Holders of Akero Therapeutics, Inc. - COMMON STOCK (AKRO) as of Q2 2022
115 filings reported holding AKRO - Akero Therapeutics, Inc. - COMMON STOCK as of Q2 2022.
Akero Therapeutics, Inc. - COMMON STOCK (AKRO) has 102 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 34.7M shares
of 79.4M outstanding shares and own 43.73% of the company stock.
Largest 10 shareholders include Skorpios Trust (4.91M shares), JANUS HENDERSON GROUP PLC (3.07M shares), ALKEON CAPITAL MANAGEMENT LLC (2.62M shares), Point72 Asset Management, L.P. (2.3M shares), Atlas Venture Life Science Advisors, LLC (2.23M shares), venBio Partners LLC (2.17M shares), BlackRock Inc. (2.09M shares), Yiheng Capital Management, L.P. (1.88M shares), Redmile Group, LLC (1.59M shares), and HHLR ADVISORS, LTD. (1.36M shares).
This table shows the top 102 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.